Company: CDT
Filing Date: 2025-08-12
Form Type: 424B3
Source: 0001641172-25-023191
Chunk: 7

Company: CDT Equity Inc.
Filing Date: 2025-08-12
Form: 424B3
Chunk 7
---
, 2025, Harold Eytan and the Company entered into the Consulting Agreement in which Harold Eytan will provide services to optimize strategies of the Company related to cryptocurrency. Such strategies include the potential adoption of a cryptocurrency treasury reserve strategy. For services rendered, the Company has agreed to compensate Harold Eytan 95,618 shares to satisfy the $240,000 fee due to Harold Eytan pursuant to the Consulting Agreement. Harold Eytan is not a related party to the Company.

E3 Fund SP

On May 20, 2025, the Company issued 4,868 Shares to E3 Fund SP, in connection with services provided in March 2025 regarding the negotiation and resolution of previously issued indebtedness (the “E3 Issuance”).

Corporate Information

On September 22, 2023, a merger transaction
(the “Business Combination”) between Conduit Pharmaceuticals Limited (“Old Conduit”), Murphy Canyon Acquisition
Corp (“MURF”) and Conduit Merger Sub, Inc., a Cayman Islands exempted company and a wholly owned subsidiary of MURF (“Merger
Sub”), was completed pursuant to the Agreement and Plan of Merger, dated November 8, 2022, as amended, (the “Merger Agreement”).
Pursuant to the terms of the Merger Agreement, at the closing, (i) Merger Sub merged with and into Old Conduit, with Old Conduit surviving
the Business Combination as a wholly-owned subsidiary of MURF, and (ii) MURF changed its name from Murphy Canyon Acquisition Corp. to
Conduit Pharmaceuticals Inc. Effective August 5, 2025, we changed our name from Conduit Pharmaceuticals Inc. to CDT Equity Inc. Our
change to CDT Equity Inc. reflects the evolution of our strategy as a data-driven biotech development company focused on identifying,
enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships.

Our principal executive offices are located at 4581 Tamiami Trail North, Suite 200, Naples, Florida 34103, and our telephone number is (646) 491-9132. Our website address is http://www.conduitpharma.com.The information contained on or otherwise accessible through our website is not part of this prospectus.

| 4 |

<div align='center'>The Offering</div>

| Shares                                            
 of Common                                         
 Stock offered by the                              
 Selling Stockholders                              |     | 255,285